二肽基肽酶-4抑制剂在2型糖尿病治疗中的应用(2)
[7]Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidylpeptidase-4 reduces glycemia, sustains insulin level, and reduce glucagons levels in type 2 diabetes, J Clin Endocrinol Metab, 2004;89:2078-84
[8]Ahren B,PaciniG, Foley IE, Schweizer A, improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vidaglipitin in metformin-treated patients with type 2 diabetes over 1 year, Diabetes Care, 2005;28:1936-40
[9]Deacon CF, Ahren B, Holst JJ: Inhibitors of dipeptidyl peptidase-IV: a novel approach to prevention and treatment of type2 diabetes. Expert Opin Investing Drugs 13:1091-1102,2004
[10]Drucker DJ: Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Clin Pract Endocrinol Metab 1:22-31,2005
[11] Scott R, Wu L, Sanchez M, Stein P: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61: 171-180, 2007
[12]Bosi E, Camisaca RP, Collober C, Rochotte E, Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care in press, 2007
[13]Nathwani A: The use of vildagliptin for treatment of patients with type 2 diabetes. Latebreaking clinical study presented at ADA
[14]Fonseca V, DeJager S, Albrecht D, Shirt L, Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2D). Diabetes 55: suppl 1: A1 11,2006., 百拇医药(李兴)
[8]Ahren B,PaciniG, Foley IE, Schweizer A, improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vidaglipitin in metformin-treated patients with type 2 diabetes over 1 year, Diabetes Care, 2005;28:1936-40
[9]Deacon CF, Ahren B, Holst JJ: Inhibitors of dipeptidyl peptidase-IV: a novel approach to prevention and treatment of type2 diabetes. Expert Opin Investing Drugs 13:1091-1102,2004
[10]Drucker DJ: Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Clin Pract Endocrinol Metab 1:22-31,2005
[11] Scott R, Wu L, Sanchez M, Stein P: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61: 171-180, 2007
[12]Bosi E, Camisaca RP, Collober C, Rochotte E, Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care in press, 2007
[13]Nathwani A: The use of vildagliptin for treatment of patients with type 2 diabetes. Latebreaking clinical study presented at ADA
[14]Fonseca V, DeJager S, Albrecht D, Shirt L, Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2D). Diabetes 55: suppl 1: A1 11,2006., 百拇医药(李兴)